Zhaoyan New Drug: Q3 Net Profit Rises 821.27% Year on Year to RMB 182 Million

36Kr learned from an announcement by Zhaoyan New Drug that in the third quarter of 2026 the company achieved operating revenue of RMB 484 million, up 53.01% year on year; net profit attributable to shareholders of the parent company was RMB 182 million, up 821.27% year on year; and net profit attributable to shareholders of the parent company after deducting non-recurring items was RMB 182 million, up 2,938.46% year on year. In the first three quarters of 2026, the company achieved operating revenue of RMB 1.188 billion, up 20.60% year on year; net profit attributable to shareholders of the parent company was RMB 930 million, up 1,051.94% year on year; and net profit attributable to shareholders of the parent company after deducting non-recurring items was RMB 881 million, up 2,933.08% year on year.